[Form 4] Revolution Medicines, Inc. Insider Trading Activity
Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, reported a sale of 13,411 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. The filing states the sale was made pursuant to a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting.
Following the reported transaction, the filing shows 452,309 shares beneficially owned directly, and additional indirect holdings of 20,424, 20,424, and 465,604 shares held by three trusts. The form is signed by an attorney-in-fact on behalf of Mr. Goldsmith.
Mark A. Goldsmith, presidente e amministratore delegato di Revolution Medicines, ha riferito la vendita di 13.411 azioni ordinarie dell'emittente il 16/09/2025 a un prezzo riportato di 45,8249$ per azione. La compilazione indica che la vendita è stata effettuata ai sensi di una lettera di istruzioni Rule 10b5-1 adottata il 31 maggio 2023 per soddisfare l'obbligo di ritenuta fiscale del soggetto segnalante al vesting degli RSU. A seguito della transazione segnalata, la compilazione mostra che detiene direttamente 452.309 azioni in modo beneficiante, e ulteriori detenzioni indirette di 20.424, 20.424, e 465.604 azioni detenute da tre trust. Il modulo è firmato da un procuratore-in-fatto per conto del Signor Goldsmith.
Mark A. Goldsmith, presidente y director ejecutivo de Revolution Medicines, informó la venta de 13,411 acciones ordinarias del emisor el 16/09/2025 a un precio reportado de 45,8249$ por acción. El archivo indica que la venta se realizó conforme a una carta de instrucciones Rule 10b5-1 adoptada el 31 de mayo de 2023 para cumplir la obligación de retención de impuestos del informante al vesting de las RSU. Tras la operación reportada, el archivo muestra que posee directamente 452.309 acciones beneficia de manera directa, y participaciones indirectas adicionales de 20.424, 20.424 y 465.604 acciones en tres fideicomisos. El formulario está firmado por un apoderado en nombre del Sr. Goldsmith.
Mark A. Goldsmith, Revolution Medicines의 회장 겸 최고경영자, 2025년 9월 16일에 일반주 13,411주를 매도하였으며 주당 보고 가격은 45.8249달러로 보고되었습니다. 제출서는 RSU의 vesting에 따른 납세 withholding 의무를 충족하기 위해 2023년 5월 31일에 채택된 Rule 10b5-1 지시서에 따라 매도가 이루어졌다고 명시합니다. 보고된 거래 이후 제출서는 직접 소유한 이익실현 주식 452,309주와 20,424주, 20,424주, 465,604주 등 세 신탁이 보유한 간접 주식이 추가로 있음을 보여줍니다. 양식은 Goldsmith 씨를 대신하여 법정대리인이 서명했습니다.
Mark A. Goldsmith, président et directeur général de Revolution Medicines, a déclaré la vente de 13 411 actions ordinaires de l’émetteur le 16/09/2025 à un prix déclaré de 45,8249$ par action. Le dépôt indique que la vente a été réalisée en vertu d’une lettre d’instructions Rule 10b5-1 adoptée le 31 mai 2023 pour satisfaire l’obligation de retenue fiscale de la personne déclarant lors du vesting des RSU. Après la transaction signalée, le dossier indique que le détenteur bénéficie directement de 452 309 actions et des positions indirectes supplémentaires de 20 424, 20 424 et 465 604 actions détenues par trois fidéicomisses. Le formulaire est signé par un mandataire agissant au nom de M. Goldsmith.
Mark A. Goldsmith, Präsident und Chief Executive Officer von Revolution Medicines, meldete den Verkauf von 13.411 Stammaktien des Emittenten am 16.09.2025 zu einem angegebenen Kurs von 45,8249 USD pro Aktie. Die Einreichung besagt, dass der Verkauf gemäß einem am 31. Mai 2023 angenommenen Rule-10b5-1-Anweisungsverzeichnis erfolgt sei, um die steuerliche Abzugspflicht der meldenden Person bei RSU-Vesting zu erfüllen. Nach der gemeldeten Transaktion zeigt die Einreichung, dass direkt und wirtschaftlich 452.309 Aktien gehalten werden, sowie zusätzliche indirekte Bestände von 20.424, 20.424 und 465.604 Aktien, gehalten von drei Trusts. Das Formular ist von einem Bevollmächtigten im Namen von Herrn Goldsmith unterzeichnet.
أعلن Mark A. Goldsmith، رئيس مجلس الإدارة والمدير التنفيذي لشركة Revolution Medicines، عن بيع 13,411 سهماً من الأسهم العادية للمصدر في 16/09/2025 بسعر تقريبي 45.8249 دولاراً للسهم. وتذكر الوثيقة أن البيع تم بموجب خطاب تعليمات Rule 10b5-1 اعتمد في 31 مايو 2023 لتلبية التزام الاحتجاز الضريبي للشخص المبلغ عنه عند استحقاق RSU. وبعد الصفقة المبلغ عنها، يظهر الملف أن الملكية مباشرةً تبلغ 452,309 سهماً، إضافة إلى حصص غير مباشرة إضافية بقيمة 20,424 و20,424 و465,604 سهماً مملوكة لثلاثة صناديق ائتمانية. النموذج موقع من وكيل نيابة نيابةً باسم السيد Goldsmith.
Mark A. Goldsmith， Revolution Medicines 的总裁兼首席执行官，报道在 2025-09-16 出售了 13,411 股发行人普通股，披露价为每股 45.8249 美元。该备案称该出售是根据于 2023 年 5 月 31 日通过的 Rule 10b5-1 指示函执行，以满足报告人就 RSU 的归属时的税收扣缴义务。报告交易后，备案显示直接受益持有 452,309 股，以及由三家信托间接持有的额外 20,424、20,424 和 465,604 股。该表格由代表 Goldsmith 先生的代理人签署。
- Transaction executed under a Rule 10b5-1 plan, indicating pre-established, compliant trading for tax withholding
- Timely disclosure filed on Form 4 and signed by an authorized attorney-in-fact
- Insider retains substantial ownership with combined direct and indirect holdings reported in the filing
- Reported sale of 13,411 shares reduces the reporting person’s direct holdings
- Price-sensitive transaction could be interpreted by some investors as insider liquidity, though context is provided
Insights
TL;DR: Insider sale appears routine tax-withholding under a pre-established 10b5-1 plan and is not an explicit signal of company performance.
The transaction discloses a sale of 13,411 shares at $45.8249 executed under a Rule 10b5-1 plan to satisfy taxes on vested RSUs. Such automated plans are commonly used to avoid timing issues and reduce perception of opportunistic trading. The sale represents a small fraction of the reporting person's combined direct and indirect holdings, which total over 900,000 shares across listed accounts and trusts, so the impact on ownership percentage is limited. No derivative transactions or other compensatory awards are reported on this form.
TL;DR: Disclosure demonstrates governance compliance through Rule 10b5-1 execution and timely Section 16 reporting.
The Form 4 clearly states the sale was pursuant to a 10b5-1 instruction adopted May 31, 2023, which supports pre-established, rule-compliant trading. The filing includes detailed indirect ownership via three trusts and is signed by an attorney-in-fact, indicating delegated execution and proper documentation. There are no indications of unusual related-party transfers or sudden changes in compensation structure on this filing.
Mark A. Goldsmith, presidente e amministratore delegato di Revolution Medicines, ha riferito la vendita di 13.411 azioni ordinarie dell'emittente il 16/09/2025 a un prezzo riportato di 45,8249$ per azione. La compilazione indica che la vendita è stata effettuata ai sensi di una lettera di istruzioni Rule 10b5-1 adottata il 31 maggio 2023 per soddisfare l'obbligo di ritenuta fiscale del soggetto segnalante al vesting degli RSU. A seguito della transazione segnalata, la compilazione mostra che detiene direttamente 452.309 azioni in modo beneficiante, e ulteriori detenzioni indirette di 20.424, 20.424, e 465.604 azioni detenute da tre trust. Il modulo è firmato da un procuratore-in-fatto per conto del Signor Goldsmith.
Mark A. Goldsmith, presidente y director ejecutivo de Revolution Medicines, informó la venta de 13,411 acciones ordinarias del emisor el 16/09/2025 a un precio reportado de 45,8249$ por acción. El archivo indica que la venta se realizó conforme a una carta de instrucciones Rule 10b5-1 adoptada el 31 de mayo de 2023 para cumplir la obligación de retención de impuestos del informante al vesting de las RSU. Tras la operación reportada, el archivo muestra que posee directamente 452.309 acciones beneficia de manera directa, y participaciones indirectas adicionales de 20.424, 20.424 y 465.604 acciones en tres fideicomisos. El formulario está firmado por un apoderado en nombre del Sr. Goldsmith.
Mark A. Goldsmith, Revolution Medicines의 회장 겸 최고경영자, 2025년 9월 16일에 일반주 13,411주를 매도하였으며 주당 보고 가격은 45.8249달러로 보고되었습니다. 제출서는 RSU의 vesting에 따른 납세 withholding 의무를 충족하기 위해 2023년 5월 31일에 채택된 Rule 10b5-1 지시서에 따라 매도가 이루어졌다고 명시합니다. 보고된 거래 이후 제출서는 직접 소유한 이익실현 주식 452,309주와 20,424주, 20,424주, 465,604주 등 세 신탁이 보유한 간접 주식이 추가로 있음을 보여줍니다. 양식은 Goldsmith 씨를 대신하여 법정대리인이 서명했습니다.
Mark A. Goldsmith, président et directeur général de Revolution Medicines, a déclaré la vente de 13 411 actions ordinaires de l’émetteur le 16/09/2025 à un prix déclaré de 45,8249$ par action. Le dépôt indique que la vente a été réalisée en vertu d’une lettre d’instructions Rule 10b5-1 adoptée le 31 mai 2023 pour satisfaire l’obligation de retenue fiscale de la personne déclarant lors du vesting des RSU. Après la transaction signalée, le dossier indique que le détenteur bénéficie directement de 452 309 actions et des positions indirectes supplémentaires de 20 424, 20 424 et 465 604 actions détenues par trois fidéicomisses. Le formulaire est signé par un mandataire agissant au nom de M. Goldsmith.
Mark A. Goldsmith, Präsident und Chief Executive Officer von Revolution Medicines, meldete den Verkauf von 13.411 Stammaktien des Emittenten am 16.09.2025 zu einem angegebenen Kurs von 45,8249 USD pro Aktie. Die Einreichung besagt, dass der Verkauf gemäß einem am 31. Mai 2023 angenommenen Rule-10b5-1-Anweisungsverzeichnis erfolgt sei, um die steuerliche Abzugspflicht der meldenden Person bei RSU-Vesting zu erfüllen. Nach der gemeldeten Transaktion zeigt die Einreichung, dass direkt und wirtschaftlich 452.309 Aktien gehalten werden, sowie zusätzliche indirekte Bestände von 20.424, 20.424 und 465.604 Aktien, gehalten von drei Trusts. Das Formular ist von einem Bevollmächtigten im Namen von Herrn Goldsmith unterzeichnet.
FAQ
What did Mark A. Goldsmith report on Form 4 for Revolution Medicines (RVMD)?
Why was the sale made according to the Form 4 filing?
How many shares does the reporting person beneficially own after the transaction?
Was any derivative or option transaction reported on this Form 4?
Who signed the Form 4 and when?
